Share Price and Basic Stock Data
Last Updated: December 10, 2025, 10:01 pm
| PEG Ratio | -4.22 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Prolife Industries Ltd operates in the dyes and pigments sector, a niche that has shown resilience over the years. The company’s revenue trajectory has been quite dynamic, with reported sales of ₹78.15 Cr in FY 2023, a notable increase from ₹73.08 Cr in FY 2022. However, the latest figures reveal a decline in the recent quarters, with sales recorded at ₹26.96 Cr for Mar 2024 and further dropping to ₹26.68 Cr in Sep 2024. This could signal potential challenges in maintaining growth momentum, especially considering the competitive landscape of the industry. The sales peak in Mar 2021 at ₹73.50 Cr and subsequent fluctuations may indicate volatility in demand or operational hurdles. Investors should monitor these trends closely, as consistent revenue generation is crucial for sustainability in this sector.
Profitability and Efficiency Metrics
When it comes to profitability, Prolife Industries presents a mixed bag. The operating profit margin (OPM) stood at a stark 1.98% for Mar 2025, down from a more favorable 20.79% in Mar 2024, indicating a significant drop in operational efficiency. Net profit for FY 2025 was recorded at ₹4.68 Cr, showcasing a decrease from ₹8.76 Cr in FY 2024. The interest coverage ratio appears strong at 23.12x, suggesting that the company comfortably meets its interest obligations. However, the decline in margins raises questions about cost management and pricing power in a potentially tightening market. The cash conversion cycle (CCC) lengthened to 94 days, indicating that the company is taking longer to convert its investments in inventory and receivables into cash, which could strain liquidity.
Balance Sheet Strength and Financial Ratios
Prolife Industries boasts a robust balance sheet with total borrowings of just ₹0.27 Cr, reflecting a conservative financial strategy with minimal debt exposure. This is further underscored by a long-term debt-to-equity ratio of 0.05, which positions the company in a comfortable zone regarding leverage. The reported reserves have grown to ₹42.87 Cr, providing a cushion for future investments or unforeseen challenges. However, the price-to-book value ratio at 1.98x suggests that the stock might be trading at a premium compared to its book value. The current ratio of 6.99 indicates excellent short-term liquidity, but it also raises questions about whether the company is effectively utilizing its assets to generate revenue. Overall, while the balance sheet appears strong, the efficiency metrics warrant attention.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Prolife Industries reveals significant promoter confidence, with promoters holding a steady 73.74% stake as of Mar 2025. This suggests that the management is committed to the long-term vision of the company, which can be a positive signal for retail investors. The public shareholding stands at 26.26%, reflecting a healthy distribution of shares. Interestingly, the number of shareholders has increased from 133 in Sep 2021 to 487 by Sep 2025, indicating growing interest and possibly rising investor confidence in the company. However, the lack of participation from Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) might point to a cautious sentiment among larger investors, which could be a concern for retail investors looking for stability.
Outlook, Risks, and Final Insight
Looking ahead, Prolife Industries faces a dual-edged sword. On one hand, its strong balance sheet and low debt levels provide a solid foundation for potential growth. On the other hand, the recent decline in revenues and profitability metrics raises red flags about operational efficiency and market competitiveness. The company must navigate these challenges carefully, especially in a sector that can be sensitive to global economic shifts and raw material costs. Retail investors should consider the volatility in revenue and profit margins as risk factors while weighing the company’s strengths in liquidity and balance sheet health. In a landscape where external factors can heavily influence performance, a cautious approach is advisable for those looking to invest in Prolife Industries.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Prolife Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Deepak Chemtex Ltd | 123 Cr. | 113 | 175/93.5 | 14.9 | 52.4 | 0.00 % | 28.1 % | 20.9 % | 10.0 |
| Prolife Industries Ltd | 32.2 Cr. | 78.8 | 361/75.0 | 13.4 | 115 | 0.38 % | 14.4 % | 10.8 % | 10.0 |
| Industry Average | 123.00 Cr | 95.90 | 14.15 | 83.70 | 0.19% | 21.25% | 15.85% | 10.00 |
Quarterly Result
| Metric | Mar 2019 | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.91 | 23.27 | 27.18 | 33.33 | 40.26 | 34.89 | 38.31 | 42.96 | 35.36 | 29.86 | 26.96 | 26.68 | 28.79 |
| Expenses | 12.65 | 21.07 | 23.86 | 29.09 | 36.31 | 31.05 | 36.18 | 38.44 | 31.15 | 22.93 | 22.08 | 21.58 | 28.22 |
| Operating Profit | 3.26 | 2.20 | 3.32 | 4.24 | 3.95 | 3.84 | 2.13 | 4.52 | 4.21 | 6.93 | 4.88 | 5.10 | 0.57 |
| OPM % | 20.49% | 9.45% | 12.21% | 12.72% | 9.81% | 11.01% | 5.56% | 10.52% | 11.91% | 23.21% | 18.10% | 19.12% | 1.98% |
| Other Income | -0.14 | 0.68 | 1.10 | 0.23 | 0.39 | 0.51 | 1.11 | 0.85 | 1.33 | 0.51 | 1.08 | 0.45 | 1.63 |
| Interest | 0.51 | 0.49 | 0.10 | 0.29 | 0.20 | 0.25 | 0.21 | 0.39 | 0.03 | 0.20 | 0.13 | 0.18 | 0.15 |
| Depreciation | 0.58 | 0.51 | 0.52 | 0.50 | 0.43 | 0.48 | 0.68 | 0.62 | 0.63 | 0.62 | 0.59 | 0.56 | 0.54 |
| Profit before tax | 2.03 | 1.88 | 3.80 | 3.68 | 3.71 | 3.62 | 2.35 | 4.36 | 4.88 | 6.62 | 5.24 | 4.81 | 1.51 |
| Tax % | 23.65% | 29.79% | 28.42% | 26.09% | 25.34% | 20.72% | 39.15% | 20.87% | 28.89% | 25.08% | 27.48% | 21.83% | 38.41% |
| Net Profit | 1.55 | 1.32 | 2.72 | 2.73 | 2.77 | 2.87 | 1.43 | 3.45 | 3.46 | 4.96 | 3.80 | 3.75 | 0.92 |
| EPS in Rs | 3.79 | 3.22 | 6.64 | 6.67 | 6.77 | 7.01 | 3.49 | 8.43 | 8.45 | 12.11 | 9.28 | 9.16 | 2.25 |
Last Updated: May 31, 2025, 8:03 am
Below is a detailed analysis of the quarterly data for Prolife Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 28.79 Cr.. The value appears strong and on an upward trend. It has increased from 26.68 Cr. (Sep 2024) to 28.79 Cr., marking an increase of 2.11 Cr..
- For Expenses, as of Mar 2025, the value is 28.22 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.58 Cr. (Sep 2024) to 28.22 Cr., marking an increase of 6.64 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.57 Cr.. The value appears to be declining and may need further review. It has decreased from 5.10 Cr. (Sep 2024) to 0.57 Cr., marking a decrease of 4.53 Cr..
- For OPM %, as of Mar 2025, the value is 1.98%. The value appears to be declining and may need further review. It has decreased from 19.12% (Sep 2024) to 1.98%, marking a decrease of 17.14%.
- For Other Income, as of Mar 2025, the value is 1.63 Cr.. The value appears strong and on an upward trend. It has increased from 0.45 Cr. (Sep 2024) to 1.63 Cr., marking an increase of 1.18 Cr..
- For Interest, as of Mar 2025, the value is 0.15 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.18 Cr. (Sep 2024) to 0.15 Cr., marking a decrease of 0.03 Cr..
- For Depreciation, as of Mar 2025, the value is 0.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.56 Cr. (Sep 2024) to 0.54 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.51 Cr.. The value appears to be declining and may need further review. It has decreased from 4.81 Cr. (Sep 2024) to 1.51 Cr., marking a decrease of 3.30 Cr..
- For Tax %, as of Mar 2025, the value is 38.41%. The value appears to be increasing, which may not be favorable. It has increased from 21.83% (Sep 2024) to 38.41%, marking an increase of 16.58%.
- For Net Profit, as of Mar 2025, the value is 0.92 Cr.. The value appears to be declining and may need further review. It has decreased from 3.75 Cr. (Sep 2024) to 0.92 Cr., marking a decrease of 2.83 Cr..
- For EPS in Rs, as of Mar 2025, the value is 2.25. The value appears to be declining and may need further review. It has decreased from 9.16 (Sep 2024) to 2.25, marking a decrease of 6.91.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.95 | 19.58 | 22.19 | 27.14 | 27.20 | 29.58 | 50.38 | 73.50 | 73.08 | 78.15 | 56.81 | 55.35 |
| Expenses | 17.49 | 17.76 | 20.39 | 24.60 | 23.65 | 25.38 | 44.82 | 65.28 | 67.10 | 69.41 | 45.00 | 49.67 |
| Operating Profit | 1.46 | 1.82 | 1.80 | 2.54 | 3.55 | 4.20 | 5.56 | 8.22 | 5.98 | 8.74 | 11.81 | 5.68 |
| OPM % | 7.70% | 9.30% | 8.11% | 9.36% | 13.05% | 14.20% | 11.04% | 11.18% | 8.18% | 11.18% | 20.79% | 10.26% |
| Other Income | 0.10 | 0.31 | 0.45 | 0.10 | 0.27 | 0.46 | 1.78 | 0.62 | 1.63 | 2.18 | 1.59 | 2.08 |
| Interest | 0.87 | 1.11 | 1.01 | 0.84 | 0.84 | 0.91 | 0.63 | 0.52 | 0.48 | 0.43 | 0.33 | 0.34 |
| Depreciation | 0.29 | 0.40 | 0.42 | 0.47 | 0.89 | 0.93 | 1.03 | 0.93 | 1.16 | 1.25 | 1.21 | 1.10 |
| Profit before tax | 0.40 | 0.62 | 0.82 | 1.33 | 2.09 | 2.82 | 5.68 | 7.39 | 5.97 | 9.24 | 11.86 | 6.32 |
| Tax % | 45.00% | 37.10% | 35.37% | 33.83% | 28.23% | 28.01% | 28.87% | 25.58% | 27.97% | 25.11% | 26.14% | 25.79% |
| Net Profit | 0.22 | 0.40 | 0.53 | 0.87 | 1.50 | 2.04 | 4.04 | 5.50 | 4.30 | 6.91 | 8.76 | 4.68 |
| EPS in Rs | 1.47 | 2.68 | 3.55 | 2.13 | 3.66 | 4.98 | 9.87 | 13.43 | 10.50 | 16.88 | 21.40 | 11.43 |
| Dividend Payout % | 20.32% | 8.94% | 7.03% | 9.40% | 6.82% | 6.01% | 3.04% | 2.23% | 2.85% | 1.78% | 2.33% | 2.62% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 81.82% | 32.50% | 64.15% | 72.41% | 36.00% | 98.04% | 36.14% | -21.82% | 60.70% | 26.77% | -46.58% |
| Change in YoY Net Profit Growth (%) | 0.00% | -49.32% | 31.65% | 8.26% | -36.41% | 62.04% | -61.90% | -57.96% | 82.52% | -33.92% | -73.35% |
Prolife Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 2% |
| 3 Years: | -9% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 3% |
| 3 Years: | 3% |
| TTM: | -47% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | -6% |
| 1 Year: | -50% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 20% |
| 3 Years: | 19% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 12:45 pm
Balance Sheet
Last Updated: December 4, 2025, 1:50 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.49 | 1.49 | 1.49 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 |
| Reserves | 1.04 | 1.53 | 2.10 | 4.59 | 6.00 | 8.03 | 11.92 | 17.30 | 21.48 | 28.27 | 36.90 | 41.38 | 42.87 |
| Borrowings | 9.60 | 10.10 | 8.61 | 5.07 | 4.82 | 7.15 | 7.71 | 5.49 | 4.71 | 1.92 | 3.81 | 2.58 | 0.27 |
| Other Liabilities | 4.07 | 4.57 | 3.84 | 4.77 | 6.22 | 7.42 | 11.94 | 21.75 | 25.15 | 6.88 | 7.12 | 5.27 | 13.74 |
| Total Liabilities | 16.20 | 17.69 | 16.04 | 18.52 | 21.13 | 26.69 | 35.66 | 48.63 | 55.43 | 41.16 | 51.92 | 53.32 | 60.97 |
| Fixed Assets | 2.29 | 2.73 | 3.21 | 8.11 | 9.56 | 10.04 | 9.60 | 9.34 | 11.43 | 11.36 | 11.29 | 10.51 | 7.55 |
| CWIP | 0.13 | 0.13 | 0.57 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 2.86 | 2.87 | 2.81 | 1.52 | 1.77 | 1.76 | 1.22 | 1.22 | 1.22 | 1.21 | 1.21 | 1.21 | 3.58 |
| Other Assets | 10.92 | 11.96 | 9.45 | 8.36 | 9.80 | 14.89 | 24.84 | 38.07 | 42.78 | 28.59 | 39.42 | 41.60 | 49.84 |
| Total Assets | 16.20 | 17.69 | 16.04 | 18.52 | 21.13 | 26.69 | 35.66 | 48.63 | 55.43 | 41.16 | 51.92 | 53.32 | 60.97 |
Below is a detailed analysis of the balance sheet data for Prolife Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.09 Cr..
- For Reserves, as of Sep 2025, the value is 42.87 Cr.. The value appears strong and on an upward trend. It has increased from 41.38 Cr. (Mar 2025) to 42.87 Cr., marking an increase of 1.49 Cr..
- For Borrowings, as of Sep 2025, the value is 0.27 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2.58 Cr. (Mar 2025) to 0.27 Cr., marking a decrease of 2.31 Cr..
- For Other Liabilities, as of Sep 2025, the value is 13.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.27 Cr. (Mar 2025) to 13.74 Cr., marking an increase of 8.47 Cr..
- For Total Liabilities, as of Sep 2025, the value is 60.97 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 53.32 Cr. (Mar 2025) to 60.97 Cr., marking an increase of 7.65 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7.55 Cr.. The value appears to be declining and may need further review. It has decreased from 10.51 Cr. (Mar 2025) to 7.55 Cr., marking a decrease of 2.96 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 3.58 Cr.. The value appears strong and on an upward trend. It has increased from 1.21 Cr. (Mar 2025) to 3.58 Cr., marking an increase of 2.37 Cr..
- For Other Assets, as of Sep 2025, the value is 49.84 Cr.. The value appears strong and on an upward trend. It has increased from 41.60 Cr. (Mar 2025) to 49.84 Cr., marking an increase of 8.24 Cr..
- For Total Assets, as of Sep 2025, the value is 60.97 Cr.. The value appears strong and on an upward trend. It has increased from 53.32 Cr. (Mar 2025) to 60.97 Cr., marking an increase of 7.65 Cr..
Notably, the Reserves (42.87 Cr.) exceed the Borrowings (0.27 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -8.14 | -8.28 | -6.81 | -2.53 | -1.27 | -2.95 | -2.15 | 2.73 | 1.27 | 6.82 | 8.00 | 3.10 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53.16 | 62.64 | 63.66 | 57.56 | 38.11 | 100.44 | 52.16 | 78.46 | 83.76 | 49.55 | 34.44 | 55.79 |
| Inventory Days | 162.19 | 170.77 | 69.16 | 43.03 | 65.17 | 37.05 | 62.59 | 52.32 | 76.79 | 39.40 | 63.68 | 68.39 |
| Days Payable | 77.54 | 91.39 | 68.73 | 71.78 | 104.12 | 104.55 | 89.97 | 124.33 | 149.89 | 25.99 | 37.71 | 30.18 |
| Cash Conversion Cycle | 137.82 | 142.02 | 64.08 | 28.81 | -0.84 | 32.93 | 24.78 | 6.45 | 10.66 | 62.96 | 60.41 | 94.00 |
| Working Capital Days | 98.62 | 87.61 | 40.46 | 54.06 | 18.12 | 54.91 | 0.07 | 8.94 | 19.58 | 57.54 | 28.98 | 70.10 |
| ROCE % | 10.63% | 13.70% | 14.93% | 16.57% | 20.31% | 21.83% | 29.03% | 30.83% | 22.57% | 29.96% | 30.83% | 14.35% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 11.43 | 21.40 | 16.89 | 10.51 | 13.43 |
| Diluted EPS (Rs.) | 11.43 | 21.40 | 16.89 | 10.51 | 13.43 |
| Cash EPS (Rs.) | 14.11 | 24.36 | 19.94 | 13.33 | 15.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 111.07 | 100.14 | 79.04 | 62.46 | 52.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 111.07 | 100.14 | 79.04 | 62.46 | 52.25 |
| Dividend / Share (Rs.) | 0.30 | 0.50 | 0.30 | 0.30 | 0.30 |
| Revenue From Operations / Share (Rs.) | 135.49 | 138.79 | 191.28 | 178.80 | 179.74 |
| PBDIT / Share (Rs.) | 18.93 | 32.74 | 26.65 | 18.53 | 21.53 |
| PBIT / Share (Rs.) | 16.25 | 29.77 | 23.59 | 15.71 | 19.25 |
| PBT / Share (Rs.) | 15.43 | 28.96 | 22.55 | 14.59 | 18.05 |
| Net Profit / Share (Rs.) | 11.43 | 21.40 | 16.89 | 10.51 | 13.43 |
| PBDIT Margin (%) | 13.97 | 23.58 | 13.93 | 10.36 | 11.98 |
| PBIT Margin (%) | 11.99 | 21.45 | 12.33 | 8.78 | 10.71 |
| PBT Margin (%) | 11.39 | 20.86 | 11.79 | 8.15 | 10.04 |
| Net Profit Margin (%) | 8.43 | 15.41 | 8.82 | 5.87 | 7.47 |
| Return on Networth / Equity (%) | 10.28 | 21.36 | 21.36 | 16.82 | 25.70 |
| Return on Capital Employeed (%) | 13.67 | 26.89 | 26.13 | 20.71 | 29.84 |
| Return On Assets (%) | 8.77 | 16.87 | 16.79 | 7.76 | 11.30 |
| Long Term Debt / Equity (X) | 0.05 | 0.09 | 0.12 | 0.19 | 0.21 |
| Total Debt / Equity (X) | 0.05 | 0.09 | 0.05 | 0.18 | 0.25 |
| Asset Turnover Ratio (%) | 1.05 | 1.22 | 1.62 | 1.41 | 1.75 |
| Current Ratio (X) | 6.99 | 4.95 | 4.28 | 1.22 | 1.12 |
| Quick Ratio (X) | 5.56 | 4.11 | 2.90 | 0.74 | 0.76 |
| Inventory Turnover Ratio (X) | 9.01 | 5.57 | 5.93 | 5.78 | 7.85 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 1.40 | 1.77 | 2.85 | 2.23 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 1.23 | 1.50 | 2.24 | 1.91 |
| Earning Retention Ratio (%) | 0.00 | 98.60 | 98.23 | 97.15 | 97.77 |
| Cash Earning Retention Ratio (%) | 0.00 | 98.77 | 98.50 | 97.76 | 98.09 |
| Interest Coverage Ratio (X) | 23.12 | 40.07 | 25.77 | 16.53 | 17.93 |
| Interest Coverage Ratio (Post Tax) (X) | 14.95 | 27.19 | 17.33 | 10.37 | 12.19 |
| Enterprise Value (Cr.) | 75.27 | 68.98 | 86.71 | 71.22 | 25.38 |
| EV / Net Operating Revenue (X) | 1.36 | 1.21 | 1.11 | 0.97 | 0.34 |
| EV / EBITDA (X) | 9.71 | 5.15 | 7.95 | 9.39 | 2.88 |
| MarketCap / Net Operating Revenue (X) | 1.62 | 1.53 | 1.10 | 0.92 | 0.28 |
| Retention Ratios (%) | 0.00 | 98.59 | 98.22 | 97.14 | 97.76 |
| Price / BV (X) | 1.98 | 2.12 | 2.67 | 2.65 | 0.96 |
| Price / Net Operating Revenue (X) | 1.62 | 1.53 | 1.10 | 0.92 | 0.28 |
| EarningsYield | 0.05 | 0.10 | 0.08 | 0.06 | 0.26 |
After reviewing the key financial ratios for Prolife Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 11.43. This value is within the healthy range. It has decreased from 21.40 (Mar 24) to 11.43, marking a decrease of 9.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is 11.43. This value is within the healthy range. It has decreased from 21.40 (Mar 24) to 11.43, marking a decrease of 9.97.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.11. This value is within the healthy range. It has decreased from 24.36 (Mar 24) to 14.11, marking a decrease of 10.25.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 111.07. It has increased from 100.14 (Mar 24) to 111.07, marking an increase of 10.93.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 111.07. It has increased from 100.14 (Mar 24) to 111.07, marking an increase of 10.93.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 24) to 0.30, marking a decrease of 0.20.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 135.49. It has decreased from 138.79 (Mar 24) to 135.49, marking a decrease of 3.30.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 18.93. This value is within the healthy range. It has decreased from 32.74 (Mar 24) to 18.93, marking a decrease of 13.81.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.25. This value is within the healthy range. It has decreased from 29.77 (Mar 24) to 16.25, marking a decrease of 13.52.
- For PBT / Share (Rs.), as of Mar 25, the value is 15.43. This value is within the healthy range. It has decreased from 28.96 (Mar 24) to 15.43, marking a decrease of 13.53.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.43. This value is within the healthy range. It has decreased from 21.40 (Mar 24) to 11.43, marking a decrease of 9.97.
- For PBDIT Margin (%), as of Mar 25, the value is 13.97. This value is within the healthy range. It has decreased from 23.58 (Mar 24) to 13.97, marking a decrease of 9.61.
- For PBIT Margin (%), as of Mar 25, the value is 11.99. This value is within the healthy range. It has decreased from 21.45 (Mar 24) to 11.99, marking a decrease of 9.46.
- For PBT Margin (%), as of Mar 25, the value is 11.39. This value is within the healthy range. It has decreased from 20.86 (Mar 24) to 11.39, marking a decrease of 9.47.
- For Net Profit Margin (%), as of Mar 25, the value is 8.43. This value is within the healthy range. It has decreased from 15.41 (Mar 24) to 8.43, marking a decrease of 6.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.28. This value is below the healthy minimum of 15. It has decreased from 21.36 (Mar 24) to 10.28, marking a decrease of 11.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.67. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 13.67, marking a decrease of 13.22.
- For Return On Assets (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has decreased from 16.87 (Mar 24) to 8.77, marking a decrease of 8.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.05, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.09 (Mar 24) to 0.05, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has decreased from 1.22 (Mar 24) to 1.05, marking a decrease of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 4.95 (Mar 24) to 6.99, marking an increase of 2.04.
- For Quick Ratio (X), as of Mar 25, the value is 5.56. This value exceeds the healthy maximum of 2. It has increased from 4.11 (Mar 24) to 5.56, marking an increase of 1.45.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.01. This value exceeds the healthy maximum of 8. It has increased from 5.57 (Mar 24) to 9.01, marking an increase of 3.44.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.40 (Mar 24) to 0.00, marking a decrease of 1.40.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.23 (Mar 24) to 0.00, marking a decrease of 1.23.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.60 (Mar 24) to 0.00, marking a decrease of 98.60.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.77 (Mar 24) to 0.00, marking a decrease of 98.77.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 23.12. This value is within the healthy range. It has decreased from 40.07 (Mar 24) to 23.12, marking a decrease of 16.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 14.95. This value is within the healthy range. It has decreased from 27.19 (Mar 24) to 14.95, marking a decrease of 12.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 75.27. It has increased from 68.98 (Mar 24) to 75.27, marking an increase of 6.29.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has increased from 1.21 (Mar 24) to 1.36, marking an increase of 0.15.
- For EV / EBITDA (X), as of Mar 25, the value is 9.71. This value is within the healthy range. It has increased from 5.15 (Mar 24) to 9.71, marking an increase of 4.56.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.62. This value is within the healthy range. It has increased from 1.53 (Mar 24) to 1.62, marking an increase of 0.09.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 98.59 (Mar 24) to 0.00, marking a decrease of 98.59.
- For Price / BV (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.98, marking a decrease of 0.14.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.62. This value is within the healthy range. It has increased from 1.53 (Mar 24) to 1.62, marking an increase of 0.09.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.10 (Mar 24) to 0.05, marking a decrease of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Prolife Industries Ltd:
- Net Profit Margin: 8.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.67% (Industry Average ROCE: 21.25%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.28% (Industry Average ROE: 15.85%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 14.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.56
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 13.4 (Industry average Stock P/E: 14.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Dyes & Pigments | No. 213, G.I.D.C., Panoli, Ankleshwar Gujarat 394116 | info@prolifeindustries.in http://www.prolifeindustries.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Karan M Jolly | Managing Director |
| Mrs. Anureet Kaur Jolly | Director |
| Mr. Siddharth Raghuvanshi | Director |
| Mr. Veljibhai K Patel | Director |
| Mr. Dharmendra Pushkarna | Independent Director |
| Mr. Keshavkumar B Singh | Independent Director |
FAQ
What is the intrinsic value of Prolife Industries Ltd?
Prolife Industries Ltd's intrinsic value (as of 10 December 2025) is 133.65 which is 69.61% higher the current market price of 78.80, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 32.2 Cr. market cap, FY2025-2026 high/low of 361/75.0, reserves of ₹42.87 Cr, and liabilities of 60.97 Cr.
What is the Market Cap of Prolife Industries Ltd?
The Market Cap of Prolife Industries Ltd is 32.2 Cr..
What is the current Stock Price of Prolife Industries Ltd as on 10 December 2025?
The current stock price of Prolife Industries Ltd as on 10 December 2025 is 78.8.
What is the High / Low of Prolife Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Prolife Industries Ltd stocks is 361/75.0.
What is the Stock P/E of Prolife Industries Ltd?
The Stock P/E of Prolife Industries Ltd is 13.4.
What is the Book Value of Prolife Industries Ltd?
The Book Value of Prolife Industries Ltd is 115.
What is the Dividend Yield of Prolife Industries Ltd?
The Dividend Yield of Prolife Industries Ltd is 0.38 %.
What is the ROCE of Prolife Industries Ltd?
The ROCE of Prolife Industries Ltd is 14.4 %.
What is the ROE of Prolife Industries Ltd?
The ROE of Prolife Industries Ltd is 10.8 %.
What is the Face Value of Prolife Industries Ltd?
The Face Value of Prolife Industries Ltd is 10.0.